secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001193125-24-198392
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha reports Q2 net loss $20.9M, cash $172.7M; TSHA-102 high dose data in 1H 2025
--------------------------------------------------------------------------------

- Net loss narrowed to $20.9M ($0.09/share) from $24.6M ($0.38/share) in Q2 2023.
- Cash $172.7M at June 30; runway extended into Q4 2026 after $76.8M public offering.
- TSHA-102 low dose data showed durable improvements and no SAEs/DLTs in adult and pediatric trials.
- High dose cohort dosing started; safety/efficacy data from both REVEAL trials expected 1H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312524198392/0001193125-24-198392-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312524198392/d760391d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-198392

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer